

Caroline B Kurtz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1049393/publications.pdf>

Version: 2024-02-01

8
papers

952
citations

1464605

7
h-index

1762888

8
g-index

9
all docs

9
docs citations

9
times ranked

1011
citing authors

#	ARTICLE	IF	CITATIONS
1	An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and <i>in silico</i> simulations of enteric hyperoxaluria. <i>Molecular Systems Biology</i> , 2022, 18, e10539.	3.2	16
2	Genetically engineered <i>E. coli</i> Nissle attenuates hyperammonemia and prevents memory impairment in bile duct ligated rats. <i>Liver International</i> , 2021, 41, 1020-1032.	1.9	10
3	Safety and pharmacodynamics of an engineered <i>E. coli</i> Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. <i>Nature Metabolism</i> , 2021, 3, 1125-1132.	5.1	72
4	Developing a new class of engineered live bacterial therapeutics to treat human diseases. <i>Nature Communications</i> , 2020, 11, 1738.	5.8	214
5	An engineered <i>E. coli</i> Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	242
6	Translational Development of Microbiome-Based Therapeutics: Kinetics of <i>E. coli</i> Nissle and Engineered Strains in Humans and Nonhuman Primates. <i>Clinical and Translational Science</i> , 2018, 11, 200-207.	1.5	24
7	240 - Genetically Engineered <i>E. Coli</i> Nissle Attenuates Hyperammonemia in a Mouse Model of Hepatic Encephalopathy by Metabolizing Gut Ammonia and Increasing Urea Production. <i>Gastroenterology</i> , 2018, 154, S-1078.	0.6	1
8	Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. <i>Nature Biotechnology</i> , 2018, 36, 857-864.	9.4	373